343 related articles for article (PubMed ID: 19140569)
1. What's new in stroke? The top 10 studies of 2006-2008. Part I.
Hart RG
Pol Arch Med Wewn; 2008 Nov; 118(11):650-7. PubMed ID: 19140569
[TBL] [Abstract][Full Text] [Related]
2. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Albers GW; Amarenco P; Easton JD; Sacco RL; Teal P
Chest; 2008 Jun; 133(6 Suppl):630S-669S. PubMed ID: 18574275
[TBL] [Abstract][Full Text] [Related]
4. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
5. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
[TBL] [Abstract][Full Text] [Related]
6. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
7. [Antithrombotic therapy after cerebral ischemia].
Schellinger PD; Orberk E; Hacke W
Fortschr Neurol Psychiatr; 1997 Sep; 65(9):425-34. PubMed ID: 9417427
[TBL] [Abstract][Full Text] [Related]
8. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
[TBL] [Abstract][Full Text] [Related]
9. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
Chaturvedi S
Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
[TBL] [Abstract][Full Text] [Related]
10. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Simmons BB; Yeo A; Fung K; ;
Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
12. The approach to optimizing stroke care.
Panagos PD
Am J Emerg Med; 2008 Sep; 26(7):808-16. PubMed ID: 18774049
[TBL] [Abstract][Full Text] [Related]
13. [Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Overgaard K; Poulsen TS; Husted SE
Ugeskr Laeger; 2007 Oct; 169(40):3379-82. PubMed ID: 17953858
[TBL] [Abstract][Full Text] [Related]
14. Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Skliut M; Jamieson DG
Curr Cardiol Rep; 2008 Feb; 10(1):9-16. PubMed ID: 18416995
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet Therapy After Noncardioembolic Stroke.
Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Malloy RJ; Kanaan AO; Silva MA; Donovan JL
Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy for stroke prevention.
Hankey GJ
Curr Atheroscler Rep; 2007 Oct; 9(4):312-8. PubMed ID: 18173959
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Bath PM; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Heptinstall S; James M; Krishnan K; Markus HS; Pocock S; Ranta A; Robinson TG; Flaherty K; Scutt P; Venables GS; Woodhouse LJ; Sprigg N
Int J Stroke; 2017 Jul; 12(5):524-538. PubMed ID: 27811309
[TBL] [Abstract][Full Text] [Related]
19. [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
Schellinger PD; Jüttler E; Meyding-Lamadé UK; Schwark C
Fortschr Neurol Psychiatr; 2004 May; 72(5):270-81. PubMed ID: 15136948
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists.
Fintel DJ
Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
